ARTICLE | Company News
SkyePharma, Blue Acquisition, Paul Capital Partners deal
April 2, 2007 7:00 AM UTC
SKP completed the previously announced sale of its injectable business, including DepoDur morphine to treat post-surgical pain, to Blue Acquisition for $20 million in cash and up to $62 million in milestones, plus royalties (see BioCentury, Jan. 15). Blue Acquisition is an acquisition vehicle controlled and funded by investors including MPM Capital; OrbiMed; and Sanderling Ventures. ...